Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azetukalner in Moderate-to-Severe Major Depressive Disorder
NCT06775379Phase 3Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Azetukalner with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale, 17-item at 6 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06775379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775379.